LakeShore Biopharma Co Ltd
LSB0.627USD
0.000
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
13.02MCap. mercado
--P/E TTM
Más Datos de LakeShore Biopharma Co Ltd Compañía
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Información de LakeShore Biopharma Co Ltd
Símbolo de cotizaciónLSB
Nombre de la empresaLakeShore Biopharma Co Ltd
Fecha de salida a bolsaJul 30, 2021
Director ejecutivoMr. Dave Chenn
Número de empleados573
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
DirecciónBuilding No. 2, 38 Yongda Road
CiudadBEIJING
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísChina
Código postal102629
Teléfono
Sitio Webhttps://www.ysbiopharm.com/
Símbolo de cotizaciónLSB
Fecha de salida a bolsaJul 30, 2021
Director ejecutivoMr. Dave Chenn
Ejecutivos de LakeShore Biopharma Co Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 2 de oct
Actualizado: jue., 2 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
Otro
12.17%
Accionistas
Accionistas
Proporción
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
Otro
12.17%
Tipos de accionistas
Accionistas
Proporción
Corporation
74.87%
Individual Investor
12.67%
Investment Advisor
0.36%
Investment Advisor/Hedge Fund
0.26%
Private Equity
0.13%
Hedge Fund
0.04%
Otro
11.67%
Participación institucional
Actualizado: dom., 5 de oct
Actualizado: dom., 5 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
20
323.47K
0.78%
-1.42M
2025Q2
28
16.97M
69.54%
+11.06M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Crystal Peak Investment Inc
21.02M
51.01%
+4.03M
+23.75%
Aug 26, 2025
Apex Prospect Ltd
9.84M
23.87%
+1.00
+0.00%
Jul 11, 2025
Zhang (Yi)
4.91M
11.91%
--
--
Jun 30, 2025
Shao (Hui)
313.64K
0.76%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
116.51K
0.28%
--
--
Jun 30, 2025
HHLR Advisors, Ltd.
75.18K
0.18%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
54.80K
0.13%
-85.63K
-60.98%
Jun 30, 2025
Superstring Capital Management LP
30.79K
0.07%
--
--
Jun 30, 2025
Barclays Bank PLC
24.76K
0.06%
--
--
Jun 30, 2025
Citadel Advisors LLC
14.96K
0.04%
+4.38K
+41.35%
Jun 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Fecha
Tipo
Relación
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
